Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PW Medtech Group Ltd. ( (HK:1358) ) has shared an announcement.
Sichuan Ruijian Medical, a subsidiary of PW Medtech Group, reported a significant increase in revenue and profit for the first half of 2025, with revenue rising by 44.68% and profit by 24.77% compared to the same period in 2024. This growth was driven by increased sales orders, although it was partly offset by higher expenses in share-based compensation, staff remuneration, and R&D. The financial results underscore the subsidiary’s strong performance in the medical device sector, particularly in blood purification, enhancing the group’s market position and offering positive implications for stakeholders.
The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.
More about PW Medtech Group Ltd.
PW Medtech Group Ltd. is an investment holding company incorporated in the Cayman Islands, primarily engaged in the R&D, manufacturing, and sales of advanced infusion sets, intravenous cannula products, insulin needles, blood purification medical devices, and regenerative medical biomaterials in China. Its subsidiary, Sichuan Ruijian Medical, focuses on medical devices for blood purification.
Average Trading Volume: 2,339,445
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.07B
Find detailed analytics on 1358 stock on TipRanks’ Stock Analysis page.